CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo

The outcome of prostate cancer (PCa) patients is highly variable and depends on whether or not distant metastases occur. Multiple chromosomal deletions have been linked to early tumor marker PSA recurrence (biochemical relapse, BCR) after radical prostatectomy (RP), but their potential role for dist...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer gene therapy 2022-01, Vol.29 (1), p.49-61
Hauptverfasser: Oh-Hohenhorst, Su Jung, Tilki, Derya, Ahlers, Ann-Kristin, Suling, Anna, Hahn, Oliver, Tennstedt, Pierre, Matuszcak, Christiane, Maar, Hanna, Labitzky, Vera, Hanika, Sandra, Starzonek, Sarah, Baumgart, Simon, Johnsen, Steven A., Kluth, Martina, Sirma, Hüseyin, Simon, Ronald, Sauter, Guido, Huland, Hartwig, Schumacher, Udo, Lange, Tobias
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The outcome of prostate cancer (PCa) patients is highly variable and depends on whether or not distant metastases occur. Multiple chromosomal deletions have been linked to early tumor marker PSA recurrence (biochemical relapse, BCR) after radical prostatectomy (RP), but their potential role for distant metastasis formation is largely unknown. Here, we specifically analyzed whether deletion of the tumor suppressor CHD1 (5q21) influences the post-surgical risk of distant metastasis and whether CHD1 loss directly contributes to metastasis formation in vivo. By considering >6800 patients we found that the CHD1 deletion negatively influences metastasis-free survival in R0 patients (HR: 2.32; 95% CI: 1.61, 3.33; p  
ISSN:0929-1903
1476-5500
DOI:10.1038/s41417-020-00288-z